Moleculin Biotech (MBRX) Q3 2024 earnings summary

Executive summary

• The company is advancing Annamycin, a next-generation anthracycline, through a global, adaptive Phase 3 MIRACLE trial for relapsed/refractory AML, with first dosing expected in Q1 2025 and a focus on its non-cardiotoxic profile and significant unmet need.

• Phase II data showed a 50% complete remission rate in second-line AML patients, with high-quality responses and median survival now over seven months, nearly double literature benchmarks; median durability of complete response composite now exceeds 8 months.

• Annamycin received Orphan Drug Designation from the EMA and FDA for AML, new U.S. patents extending exclusivity through 2040, and is supported by a Scientific Advisory Board including Dr. Daniel D. Von Hoff.

• The company completed a reverse 1-for-15 stock split in March 2024, regained Nasdaq compliance in April 2024, and closed a $5.5 million financing with up to $11 million in milestone-linked warrants.

• Management is making extraordinary efforts to ensure global site productivity, including personal visits to clinical sites in Ukraine and Georgia.

Financial highlights

• Net loss for Q3 2024 was $10.6 million, compared to $5.6 million in Q3 2023; cash and cash equivalents were $9.4 million as of September 30, 2024, expected to fund operations into Q1 2025.

• Operating expenses for Q3 2024 were $7.1 million, mainly due to increased R&D costs; R&D expense was $4.9 million for Q3 2024.

• Net cash used in operating activities for the nine months ended September 30, 2024 was $18.8 million.

• No revenue was generated in the reporting periods.

• Recent R&D expenses included a significant batch of Annamycin production and accelerated sponsored research at MD Anderson.

Outlook and guidance

• MIRACLE trial site contracting and IRB approval expected in Q4 2024; first subject dosing in Q1 2025.

• Interim efficacy and safety data on 75-90 patients anticipated by mid-2026; primary efficacy data for second-line subjects expected in 2028, enabling a rolling NDA submission for accelerated approval in 2H 2028.

• Approximately $15 million is required to reach the interim data readout in mid-2026; management is seeking additional funding through equity, debt, partnerships, or other strategic options.

• The company is refining trial costs and site selection to optimize budget and operational efficiency.

• Final data readout for Annamycin STS lung metastases program expected in 2025.